VC
RNTX

Voss Capital’s Rein Therapeutics RNTX Stock Holding History

Voss Capital’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.47M Buy
5,261,921
+873,559
+20% +$1.06M 0.25% 39
2026
Q1 		$5.7M Buy
4,388,362
+144,393
+3% +$179K 0.3% 35
2025
Q4 		$4.92M Buy
4,243,969
+1,577,437
+59% +$2.17M 0.24% 39
2025
Q3 		$3.05M Buy
2,666,532
+1,232,846
+86% +$1.57M 0.15% 42
2025
Q2 		$2.01M Buy
1,433,686
+442,970
+45% +$798K 0.14% 41
2025
Q1 		$1.75M Buy
990,716
+34,521
+4% +$72.4K 0.13% 44
2024
Q4 		$2.2M Buy
+956,195
New +$2.9M 0.16% 40

Other funds holding RNTX

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Voss Capital's RNTX Position: Q2 2026 in Review

Voss Capital increased its Rein Therapeutics (RNTX) stake by 20% in Q2 2026, buying an estimated $1.06M and bringing the position to 5,261,921 shares worth $5.47M. The position accounts for 0.25% of the portfolio, ranked #39.

Voss Capital first reported a position in RNTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $5.7M in Q1 2026. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • Voss Capital held 5,261,921 shares of Rein Therapeutics worth $5.47M as of Q2 2026.
  • Voss Capital bought 873,559 Rein Therapeutics shares in Q2 2026, an estimated $1.06M.
  • Rein Therapeutics made up 0.25% of Voss Capital's portfolio in Q2 2026, its #39 holding.
  • Voss Capital first reported a position in Rein Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Voss Capital's Rein Therapeutics position peaked at $5.7M in Q1 2026.
  • 60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Voss Capital's 13F filing for Q2 2026, filed 14 Aug 2026.